Skip to main content
Mark Pennesi, MD, Ophthalmology, Portland, OR

MarkEdwardPennesiMDPhD

Ophthalmology Portland, OR

Retinal Disease

Ophthalmic Genetics

Dr. Pennesi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Pennesi's full profile

Already have an account?

Education & Training

  • University of Pennsylvania
    University of PennsylvaniaBS, Bioengineering, Summa Cum Laude, 1997
  • Oregon Health  Science University Hospital
    Oregon Health Science University HospitalFellowship, Ophthalmic Genetics and Inherited Retinal Degeneration, 2008 - 2009
  • University of California
    University of California2005 - 2008
  • Scripps Mercy Hospital
    Scripps Mercy Hospital2005 - 2005
  • Baylor College of Medicine
    Baylor College of MedicineClass of 2004
  • Baylor College of Medicine
    Baylor College of MedicinePh.D, Neuroscience, 2003 - 2003

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2006 - Present
  • OR State Medical License
    OR State Medical License 2008 - 2025
  • TX State Medical License
    TX State Medical License 2023 - 2024
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Scientist Research Award ARVO/Alcon Early Clinician, 2011
  • Travel Award International Society for Clinical Electrophysiology in Vision, 2009
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Strategies for Treating Inherited Retinal Degeneration with Large Genes That Are Not Amenable to Adeno-Associated Virus–Based Gene Replacement Therapy  
    Mark E Pennesi, Richard G Weleber, JAMA Ophthalmology
  • Disease Course in Patients with Pentosan Polysulfate Sodium–Associated Maculopathy After Drug Cessation  
    Joseph M Simonett, Mark E Pennesi, Nieraj Jain, JAMA Ophthalmology
  • Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients with Autosomal Dominant Retinitis Pigmentosa  
    David G Birch, Michael P Teske, Richard G Weleber, Robert Lindblad, Byron L Lam, Judith Warner, Gary Edd Fish, Neal L Sklaver, Mark E Pennesi, John Heckenlively, Paul ..., JAMA
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Lentiviral Vector for Gene Replacement Therapy in Stargardt Disease and Usher Syndrome Type IB.
    Wilson D, Stout JT, Weleber RG, Pennesi ME, Francis PJ, Sahel J, Mohand-Said S, Naylor S Audo I, Macula Society, Jerusalem Israel
  • Imaging the Cone Mosaic using a Commerically available Adaptive Optics Flood Illuminated Camera and Examining its Potential as an Endpoint for Clinical Trials.
    Pennesi ME, Fay JD, Faridi A, Garg AK, Chegarnov EN, Michaels KV, International Society for Clinical Electrophysiology in Vision, Valencia, Spain
  • Hand-Held Spectral-Domain Optical Coherence Tomography in the Evaluation of Patients in a Pediatric Ophthalmic Genetics Clinic.
    Pennesi ME, Courtney RJ, Francis PJ, Weleber RG, International Society for Clinical Electrophysiology in Vision, Quebec City, Montreal
  • Join now to see all

Lectures

  • SD-OCT of Mice and Men. 
    Coordes Conference, UCSF
  • Retinitis Pigmentosa. 
    Foundation Fighting Blindness, Visions Conference
  • The Advantages of Hand-held sdOCT for Studying Retinal Degeneration in Infants and Animal Models. 
    National Eye Institute
  • Join now to see all

Authored Content

  • Disease Course in Patients with Pentosan Polysulfate Sodium–Associated Maculopathy After Drug CessationJuly 2020
  • Disease Course in Patients with Pentosan Polysulfate Sodium–Associated Maculopathy After Drug CessationJuly 2020
  • Disease Course in Patients with Pentosan Polysulfate Sodium–Associated Maculopathy After Drug CessationJuly 2020

Press Mentions

  • Endogena Therapeutics Completes Dose Escalation in the Phase 1/2a Clinical Trial of EA-2353 for the Treatment of Retinitis Pigmentosa
    Endogena Therapeutics Completes Dose Escalation in the Phase 1/2a Clinical Trial of EA-2353 for the Treatment of Retinitis PigmentosaApril 5th, 2023
  • Where Should Society Draw Ethical Lines for Experimental CRISPR Gene Therapies That Appear Able to Cure Diseases?
    Where Should Society Draw Ethical Lines for Experimental CRISPR Gene Therapies That Appear Able to Cure Diseases?April 13th, 2022
  • US FDA Accepts Ocugen Inc.’s (NASDAQ: OCGN) Investigational New Drug Application TO Commence Phase 1/2 OCU400 Study
    US FDA Accepts Ocugen Inc.’s (NASDAQ: OCGN) Investigational New Drug Application TO Commence Phase 1/2 OCU400 StudyDecember 23rd, 2021
  • Join now to see all

Grant Support

  • Serotonin Receptor Modulation Of Neurotrophic Factors In The RetinaNational Eye Institute2011–2012

Professional Memberships